Pyloroplasty Versus No Pyloroplasty in Patients Undergoing Esophagectomy

Sponsor
University of Pittsburgh (Other)
Overall Status
Recruiting
CT.gov ID
NCT03740542
Collaborator
(none)
140
1
2
73.1
1.9

Study Details

Study Description

Brief Summary

This research study is a phase III randomized trial to study the value of the addition of a pyloroplasty procedure versus no pyloroplasty procedure during the performance of esophagectomy. Pyloroplasty is a type of pyloric drainage procedure.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Esophagectomy
  • Procedure: Pyloroplasty
N/A

Detailed Description

Patients selected for enrollment in this study will be adults (18-85 years of age) that have been scheduled for exploration, and possible esophagectomy. Prior to surgery, patients will be randomized to one of two groups. Group A will have a pyloroplasty performed as part of the esophagectomy procedure. Group B will not have a pyloroplasty performed. Postoperative patient outcomes will be assessed for 24 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
140 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase III Randomized Trial of Pyloroplasty Versus No Pyloroplasty in Patients Undergoing Esophagectomy
Actual Study Start Date :
Nov 27, 2018
Anticipated Primary Completion Date :
Aug 30, 2022
Anticipated Study Completion Date :
Dec 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Esophagectomy with Pyloroplasty

Esophagectomy with Pyloroplasty

Procedure: Esophagectomy
Surgical removal of part of esophagus

Procedure: Pyloroplasty
pyloric drainage procedure

Experimental: Esophagectomy without Pyloroplasty

Esophagectomy without Pyloroplasty

Procedure: Esophagectomy
Surgical removal of part of esophagus

Outcome Measures

Primary Outcome Measures

  1. pneumonia [30 days postoperatively]

    Defined as meeting 3 of 5 characteristics: fever, leukocytosis, chest x-ray (CXR) with infiltrate, positive culture from sputum, or treatment with antibiotics

  2. esophageal anastomosis leak requiring surgery [30 days postoperatively]

    Defined as a leak at the esophageal anastomosis site as evidenced by Barium Swallow Study.

Secondary Outcome Measures

  1. Mortality [30 days]

    Death within 30 days of surgery

  2. Time to start oral diet [Up to 24 months]

    Number of days from surgery to starting oral diet

  3. Quality of life assessment by completion of SF36 Quality of Life questionnaire [Prior to esophagectomy, at the first postoperative visit, and 4, 6, and 12 months after surgery]

    SF36 Quality of Life questionnaire

  4. Gastroesophageal Reflux Disease (GERD)-Health Related Quality of Life (HRQL) measured by completion of GERD HRQL questionnaire [Prior to esophagectomy, at the first postoperative visit, and 4, 6, and 12 months after surgery.]

    Gastroesophageal Reflux Disease (GERD)-Health Related Quality of Life (HRQL) questionnaire prior to esophagectomy, at the first postoperative visit, and 4, 6, and 12 months after surgery.

  5. Dysphagia as reported by patient using the Dysphagia scale [Prior to esophagectomy, at the first postoperative visit, and 4, 6, and 12 months after surgery.]

    Dysphagia scale measures swallowing difficulty on a scale of 1-5. (1=no difficulty swallowing; 2=difficulty swallowing hard solids; 3=difficulty swallowing soft solids; 4=difficulty swallowing liquids; 5=unable to swallow anything. A lower score represents a better outcome.

  6. Nasogastric tube drainage measured in milliliters [From date of surgery until date nasogastric tube is removed or date of discharge from hospital, whichever came first, assessed up to 24 months.]

    Measured in milliliters

  7. Replacement of nasogastric tube reported as number of days from tube removal to reinsertion [Up to 24 months]

    Number of days from nasogastric tube removal to reinsertion

  8. Esophageal dilations reported as the number of esophageal dilations performed [Up to 24 months]

    Number of esophageal dilations performed

  9. Length of hospital stay [From date of surgery until the date of discharge from hospital, assessed up to 24 months.]

    Number of days in hospital

  10. Aspiration as reported on radiographic imaging [Performed when clinically indicated up to 24 months postoperatively]

    Radiographic imaging reports

  11. Gastric outlet obstruction as reported on barium swallow reports [Performed when clinically indicated up to 24 months postoperatively]

    Barium swallow reports

  12. Re-admission to hospital [Up to 24 months postoperatively]

    Number of days from hospital discharge to re-admission

  13. Unexpected return to the Operating Room [Up to 24 months postoperatively]

    Procedure performed in the Operating Room

  14. Esophageal anastomotic leak not requiring surgery [Performed when clinically indicated up to 24 months postoperatively]

    Barium swallow reports

  15. Respiratory complications other than pneumonia [Performed when clinically indicated up to 24 months postoperatively]

    Radiographic imaging reports

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects must be willing to undergo esophagectomy for benign or malignant condition

  • Women and men 18-85 years of age

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2

  • Stomach is used as conduit

Exclusion Criteria:
  • Previous operations of the pylorus

  • Previous gastric resection

  • Previous gastric bypass

  • Patients who are unable to tolerate surgery

  • Participants may be enrolled and randomized on the study but may be excluded at the time of the surgery because of findings by the surgeon that preclude performing esophagectomy, or using stomach as a conduit or findings which preclude following the randomized arm.

  • Age <18 years of age or > 85 years of age

  • BMI > 50

  • Liver cirrhosis or liver failure at physician's discretion

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Cardiothoracic Surgery Pittsburgh Pennsylvania United States 15232

Sponsors and Collaborators

  • University of Pittsburgh

Investigators

  • Principal Investigator: James Luketich, MD, University of Pittsburgh

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
James Luketich, Principal Investigator, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT03740542
Other Study ID Numbers:
  • PRO18010137
First Posted:
Nov 14, 2018
Last Update Posted:
Jan 24, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Jan 24, 2022